Research Paper Volume 13, Issue 12 pp 16696—16712

Identification of an immune checkpoint gene signature that accurately predicts prognosis and immunotherapy response in endometrial carcinoma

class="figure-viewer-img"

Figure 11. TNFRSF14 knockdown promotes EC progression by enhancing EMT. (A) Western blot analysis shows TNFRSF14 protein expression in EC cell lines (HEC1B, RL-952, Hec-1B, and Ishikawa). (B) Western blot analysis shows TNFRSF14 protein levels in control and TNFRSF14-shRNA#1- and TNFRSF14-shRNA#2-transfected RL-952 cells. (CD) Transwell invasion assay and wound healing assay results show the invasiveness and migration ability of control and TNFRSF14-silenced RL-952 cells. (E) EdU incorporation assay results show the proliferation rates of control and TNFRSF14-silenced RL-952 cells. (F) Flow cytometry analysis shows the percentage apoptosis of 5-fluorouracil-treated control and TNFRSF14 knockdown RL-952 cells. (G) Western blot analysis shows expression levels of EMT-associated marker proteins, Vimentin and Snail, in control and TNFRSF14-silenced RL-952 cells.